Zydus Cadila receives final approval from USFDA for Glycopyrrolate Injection

Zydus Cadila has received final approval from the USFDA to market Glycopyrrolate Injection in the strengths of 0.2 mg/mL and 0.4 mg/2 mL (0.2 mg/mL) Single-Dose Vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) Multiple-Dose Vials, (US RLD: Robinul). Glycopyrrolate is used before surgery to decrease the volume of secretions from mouth, lungs and stomach. It can also be used either before or during surgery to maintain heart's normal beating rhythm. It is also used to counter the effects of some other medicines, which can slow heartbeat or produce excessive secretions when used during surgery. Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when rapid effect is desired or when oral medication is not tolerated. The drug will be manufactured at the group's injectables manufacturing facility at CHL-Jarod, near Vadodara (earlier known as Liva Pharmaceuticals Ltd.).

The group now has 324 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 498.40 as compared to the previous close of Rs. 494.60. The total number of shares traded during the day was 212859 in over 5775 trades.

The stock hit an intraday high of Rs. 510.00 and intraday low of 494.05. The net turnover during the day was Rs. 106382981.00.

Source : Equity Bulls

Keywords

CadilaHealthcareLimited INE010B01027 CADILAHC Pharmaceuticals USFDA GlycopyrrolateInjection